XORTX Therapeutics Inc. is a pharmaceutical company with four programs underway: One of these programs is at the pre-NDA filing stage – XRx-026 for the treatment of gout; two are clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and health of patients. Additional information on XORTX is available at www.xortx.com
Company Profile
Latest Presentation
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Pharmaceutical Preparation Manufacturing (325412)
SIC:
Pharmaceutical and Medicine Industry (3741)
Contact Information
Investor Relations
Allen Davidoff
CEO
T: 403-455-7727
adavidoff@xortx.com
Nick Rigopulos
Director of Communications
T: 617-901-0785
nick@alpineequityadv.com
Company Contact
XORTX Therapeutics Inc.
3710 – 33rd Street NW
Calgary, Alberta T2L 2M1
Canada
T: 403-455-7727
info@xortx.com